Antitrust police raid Sanofi's Hungarian HQ; Glaxo nabs FDA approval for OTC Flonase;

> Hungary's competition watchdog raided Sanofi's ($SNY) domestic headquarters as part of a probe into its wholesaler-selection practices. Report

> The FDA approved an over-the-counter version of Flonase, the allergy-fighting nasal spray from GlaxoSmithKline ($GSK); a launch is planned for next year. Report

> GlaxoSmithKline ($GSK) rolled out its once-weekly Type 2 diabetes treatment Tanzeum (albiglutide), a GLP-1 agonist, in the U.S. Release

> Ranbaxy Laboratories signed up to market Cipher Pharmaceuticals' acne drug Absorica (irotretinoin) in Brazil. Report

> CANbridge Life Sciences inked a marketing partnership with Jazz Pharmaceuticals ($JAZZ) to commercialize the oral mucositis treatment Caphosol in China. Release

> Novo Nordisk ($NVO) signed on to help feed needy families in Egypt during the holy month of Ramadan. Report

> Bayer and Amgen ($AMGN) said their cancer drug Nexavar failed to hit its primary endpoint in another Phase III breast cancer study. Report

And Finally... Want a custom bobblehead for your promo campaign? Amazon now has a 3D printing store. Report

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.